Endovascular therapy for aortic dissection

David S. Wang, Michael D. Dake

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Citations (Scopus)

Abstract

19.4 Conclusion: The recent development of endovascular stent-graft technology and its application as an alternative management strategy to medical therapy or open surgical intervention of patients with aortic dissection is an exciting and potentially valuable advance. As conventional treatments for aortic dissection and its attendant complications are often associated with significant failure rates, result in substantial morbidity and mortality, and/or do little to reduce the risk of aneurysm formation as late sequelae improved treatment options are desired. Here, we have reviewed the current clinical experience with stent-graft placement for treatment of complicated and uncomplicated acute type B dissection, retrograde type A dissection, chronic dissection, and PAU. It is imperative to first appreciate the wide array of clinical, anatomic, and temporal manifestations within the umbrella pathology of aortic dissection. Evaluation of the role of endoluminal stent-graft technology must be performed within the context of each of these subgroups through rigorous, prospective controlled investigations and compared against respective standard treatment. Although this poses a much more significant challenge, the encouraging early results highlighted here underscore the potential for stent-graft therapy to supplant conventional - and often suboptimal - treatment paradigms and to provide patients with a less invasive therapeutic alternative that may concomitantly achieve gains in survival.

Original languageEnglish (US)
Title of host publicationThoracic Aortic Diseases
PublisherSpringer Berlin Heidelberg
Pages189-198
Number of pages10
ISBN (Print)3540257349, 9783540257349
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Dissection
Stents
Transplants
Therapeutics
Technology
Aneurysm
Pathology
Morbidity
Survival
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wang, D. S., & Dake, M. D. (2006). Endovascular therapy for aortic dissection. In Thoracic Aortic Diseases (pp. 189-198). Springer Berlin Heidelberg. https://doi.org/10.1007/3-540-38309-3_19

Endovascular therapy for aortic dissection. / Wang, David S.; Dake, Michael D.

Thoracic Aortic Diseases. Springer Berlin Heidelberg, 2006. p. 189-198.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wang, DS & Dake, MD 2006, Endovascular therapy for aortic dissection. in Thoracic Aortic Diseases. Springer Berlin Heidelberg, pp. 189-198. https://doi.org/10.1007/3-540-38309-3_19
Wang DS, Dake MD. Endovascular therapy for aortic dissection. In Thoracic Aortic Diseases. Springer Berlin Heidelberg. 2006. p. 189-198 https://doi.org/10.1007/3-540-38309-3_19
Wang, David S. ; Dake, Michael D. / Endovascular therapy for aortic dissection. Thoracic Aortic Diseases. Springer Berlin Heidelberg, 2006. pp. 189-198
@inbook{bf03dfaaf4cb4efaaf5a6a27d5d356ef,
title = "Endovascular therapy for aortic dissection",
abstract = "19.4 Conclusion: The recent development of endovascular stent-graft technology and its application as an alternative management strategy to medical therapy or open surgical intervention of patients with aortic dissection is an exciting and potentially valuable advance. As conventional treatments for aortic dissection and its attendant complications are often associated with significant failure rates, result in substantial morbidity and mortality, and/or do little to reduce the risk of aneurysm formation as late sequelae improved treatment options are desired. Here, we have reviewed the current clinical experience with stent-graft placement for treatment of complicated and uncomplicated acute type B dissection, retrograde type A dissection, chronic dissection, and PAU. It is imperative to first appreciate the wide array of clinical, anatomic, and temporal manifestations within the umbrella pathology of aortic dissection. Evaluation of the role of endoluminal stent-graft technology must be performed within the context of each of these subgroups through rigorous, prospective controlled investigations and compared against respective standard treatment. Although this poses a much more significant challenge, the encouraging early results highlighted here underscore the potential for stent-graft therapy to supplant conventional - and often suboptimal - treatment paradigms and to provide patients with a less invasive therapeutic alternative that may concomitantly achieve gains in survival.",
author = "Wang, {David S.} and Dake, {Michael D.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1007/3-540-38309-3_19",
language = "English (US)",
isbn = "3540257349",
pages = "189--198",
booktitle = "Thoracic Aortic Diseases",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Endovascular therapy for aortic dissection

AU - Wang, David S.

AU - Dake, Michael D.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - 19.4 Conclusion: The recent development of endovascular stent-graft technology and its application as an alternative management strategy to medical therapy or open surgical intervention of patients with aortic dissection is an exciting and potentially valuable advance. As conventional treatments for aortic dissection and its attendant complications are often associated with significant failure rates, result in substantial morbidity and mortality, and/or do little to reduce the risk of aneurysm formation as late sequelae improved treatment options are desired. Here, we have reviewed the current clinical experience with stent-graft placement for treatment of complicated and uncomplicated acute type B dissection, retrograde type A dissection, chronic dissection, and PAU. It is imperative to first appreciate the wide array of clinical, anatomic, and temporal manifestations within the umbrella pathology of aortic dissection. Evaluation of the role of endoluminal stent-graft technology must be performed within the context of each of these subgroups through rigorous, prospective controlled investigations and compared against respective standard treatment. Although this poses a much more significant challenge, the encouraging early results highlighted here underscore the potential for stent-graft therapy to supplant conventional - and often suboptimal - treatment paradigms and to provide patients with a less invasive therapeutic alternative that may concomitantly achieve gains in survival.

AB - 19.4 Conclusion: The recent development of endovascular stent-graft technology and its application as an alternative management strategy to medical therapy or open surgical intervention of patients with aortic dissection is an exciting and potentially valuable advance. As conventional treatments for aortic dissection and its attendant complications are often associated with significant failure rates, result in substantial morbidity and mortality, and/or do little to reduce the risk of aneurysm formation as late sequelae improved treatment options are desired. Here, we have reviewed the current clinical experience with stent-graft placement for treatment of complicated and uncomplicated acute type B dissection, retrograde type A dissection, chronic dissection, and PAU. It is imperative to first appreciate the wide array of clinical, anatomic, and temporal manifestations within the umbrella pathology of aortic dissection. Evaluation of the role of endoluminal stent-graft technology must be performed within the context of each of these subgroups through rigorous, prospective controlled investigations and compared against respective standard treatment. Although this poses a much more significant challenge, the encouraging early results highlighted here underscore the potential for stent-graft therapy to supplant conventional - and often suboptimal - treatment paradigms and to provide patients with a less invasive therapeutic alternative that may concomitantly achieve gains in survival.

UR - http://www.scopus.com/inward/record.url?scp=71549119873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71549119873&partnerID=8YFLogxK

U2 - 10.1007/3-540-38309-3_19

DO - 10.1007/3-540-38309-3_19

M3 - Chapter

AN - SCOPUS:71549119873

SN - 3540257349

SN - 9783540257349

SP - 189

EP - 198

BT - Thoracic Aortic Diseases

PB - Springer Berlin Heidelberg

ER -